Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Prospective, Phase II, Double Blinded, Multicentre, Randomised Clinical Trial Comparing Combination Gemcitabine and Vandetanib Therapy With Gemcitabine Therapy Alone in Locally Advanced or Metastatic Pancreatic Carcinoma

NCT01601808 is registered in ClinicalTrials.gov with University of Liverpool as lead sponsor.

NCT NCT01601808
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01601808 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Prospective, Phase II, Double Blinded, Multicentre, Randomised Clinical Trial Comparing Combination Gemcitabine and Vandetanib Therapy With Gemcitabine Therapy Alone in Locally Advanced or Metastatic Pancreatic Carcinoma
Lead sponsor
University of Liverpool
Phase
Phase 2
Overall status
Completed
Start date
October 10, 2011
Completion date
September 5, 2018
Enrollment
142 (actual)
Sites
14

Conditions

As the registry lists them; a condition with its own page is linked.

pancreatic cancer